We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Sciex

SCIEX develops and sells scientific instrumentation, software, and services for the life science, clinical research, ... read more Featured Products: More products

Download Mobile App




New Mass Spectrometry Series Enhances Analytical Diagnostics

By LabMedica International staff writers
Posted on 12 Aug 2014
A leading mass spectrometry portfolio for analytic clinical testing has been expanded with a new series offering flexibility, exceptional sensitivity, and faster data acquisition.

SCIEX Diagnostics (Framingham, MA, USA), part of AB SCIEX, unveiled its latest products—theTriple Quad 4500MD and QTRAP 4500MD LC/MS/MS systems—at the American Association of Clinical Chemistry (AACC) Annual Meeting and Expo in Chicago, Illinois, July 29–31, 2014. More...
Expected to be available in the US and select EU countries in September 2014, the 4500MD series joins the company's growing family of in vitro diagnostic devices, including the 3200MD and IVD-MS Analyzer systems launched in 2013, as well as a series of kits for vitamin D, immunosuppressants, and newborn screening testing to be available in August 2014 for use in certain European countries.

The new 4500MD series offers exceptional sensitivity and faster data acquisition over previous systems, providing reliable results so physicians and patients have accurate answers quickly. It is a flexible LC/MS/MS platform that offers enhanced performance to enable customers developing their own applications to validate methods that require lower detection limits or higher throughput, with the peace of mind afforded by a regulatory compliant solution.

"As scientific understanding progressively evolves into improved clinical diagnostic testing, diagnostic customers who develop their own assays are turning to fast, sensitive instruments to perform routine tests with high efficiency and cost savings," said Chris Radloff, vice president of Applied Markets and Clinical Research at AB SCIEX, "By bringing the power, flexibility, reliability, and accuracy of our mass spectrometry technology to clinical testing laboratories, AB SCIEX is enabling customers to deliver high quality diagnostic information to clinicians who make decisions affecting patient care."

Related Links:

SCIEX Diagnostics
AB SCIEX


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Automated Urinalysis Solution
UN-9000
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.